Literature DB >> 24082081

Chlamydia pneumoniae infection promotes vascular smooth muscle cell migration through a Toll-like receptor 2-related signaling pathway.

Beibei Wang1, Lijun Zhang, Tengteng Zhang, Haiwei Wang, Junxia Zhang, Junyan Wei, Bingling Shen, Xin Liu, Zhelong Xu, Lijun Zhang.   

Abstract

The migration of vascular smooth muscle cells (VSMCs) from the media to the intima is proposed to be a key event in the development of atherosclerosis. Recently, we reported that Chlamydia pneumoniae infection is involved in VSMC migration. However, the exact mechanisms for C. pneumoniae infection-induced VSMC migration are not yet well elucidated. In this study, we examined the role of the Toll-like receptor 2 (TLR2) activation-related signaling pathway in VSMC migration induced by C. pneumoniae infection. An Affymetrix-based gene expression array was conducted to identify the changes of gene expression in rat primary VSMCs (rVSMCs) infected with C. pneumoniae. Both the microarray analysis and quantitative real-time reverse transcription (RT)-PCR revealed that TLR2 mRNA expression was strongly upregulated 12 h after C. pneumoniae infection. RT-PCR and Western blot analysis further showed that the expression levels of TLR2 mRNA and protein significantly increased at the different time points after infection. Immunocytochemical analysis suggested a TLR2 recruitment to the vicinity of C. pneumoniae inclusions. Cell migration assays showed that the TLR2-neutralizing antibody could significantly inhibit C. pneumoniae infection-induced rVSMC migration. In addition, C. pneumoniae infection stimulated Akt phosphorylation at Ser 473, which was obviously suppressed by the PI3K inhibitor LY294002, thereby inhibiting rVSMC migration caused by C. pneumoniae infection. Furthermore, both the infection-induced Akt phosphorylation and rVSMC migration were suppressed by the TLR2-neutralizing antibody. Taken together, these data suggest that C. pneumoniae infection can promote VSMC migration possibly through the TLR2-related signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24082081      PMCID: PMC3837995          DOI: 10.1128/IAI.01087-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

Review 1.  Toll-like receptors in the induction of the innate immune response.

Authors:  A Aderem; R J Ulevitch
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

2.  IQGAP1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation by Akt activation.

Authors:  Feng Chen; Hai Hong Zhu; Lin Fu Zhou; Shan Shan Wu; Jing Wang; Zhi Chen
Journal:  Exp Mol Med       Date:  2010-07-31       Impact factor: 8.718

3.  The titration of trachoma and inclusion blennorrhoea viruses in cell cultures.

Authors:  G FURNESS; D M GRAHAM; P REEVE
Journal:  J Gen Microbiol       Date:  1960-12

4.  Berberine inhibits HEp-2 cell invasion induced by Chlamydophila pneumoniae infection.

Authors:  Li Jun Zhang; Li Jun Zhang; Wei Quan; Bei Bei Wang; Bing Ling Shen; Teng Teng Zhang; Yi Kang
Journal:  J Microbiol       Date:  2011-11-09       Impact factor: 3.422

5.  Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.

Authors:  P Saikku; M Leinonen; K Mattila; M R Ekman; M S Nieminen; P H Mäkelä; J K Huttunen; V Valtonen
Journal:  Lancet       Date:  1988-10-29       Impact factor: 79.321

6.  C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway.

Authors:  Lingyun Zhang; Yuee Teng; Ye Zhang; Jing Liu; Ling Xu; Jinglei Qu; Kezuo Hou; Xianghong Yang; Yunpeng Liu; Xiujuan Qu
Journal:  Oncol Lett       Date:  2011-11-16       Impact factor: 2.967

7.  Toll-like receptor 2 regulates interleukin-1beta-dependent cardiomyocyte hypertrophy triggered by Trypanosoma cruzi.

Authors:  Christine A Petersen; Katherine A Krumholz; Barbara A Burleigh
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

8.  Mycobacteria directly induce cytoskeletal rearrangements for macrophage spreading and polarization through TLR2-dependent PI3K signaling.

Authors:  Elena B Lasunskaia; Mariana N N Campos; Marcelle R M de Andrade; Renato A Damatta; Thereza L Kipnis; Marcelo Einicker-Lamas; Wilmar D Da Silva
Journal:  J Leukoc Biol       Date:  2006-09-27       Impact factor: 4.962

9.  Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation.

Authors:  H D Park; Y Lee; Y K Oh; J G Jung; Y W Park; K Myung; K-H Kim; S S Koh; D-S Lim
Journal:  Oncogene       Date:  2010-08-30       Impact factor: 9.867

10.  Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis.

Authors:  Carlos Fernández-Hernando; Levente József; Deborah Jenkins; Annarita Di Lorenzo; William C Sessa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-09-17       Impact factor: 8.311

View more
  4 in total

1.  Chlamydia pneumoniae Infection and Inflammatory Diseases.

Authors:  Rebecca A Porritt; Timothy R Crother
Journal:  For Immunopathol Dis Therap       Date:  2016

2.  TLR4 rs1927911, but not TLR2 rs5743708, is associated with atherosclerotic cerebral infarction in the Southern Han population: a case-control study.

Authors:  Yanmin Song; Huarong Liu; Lili Long; Ning Zhang; Yunhai Liu
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

3.  Tollip Negatively Regulates Vascular Smooth Muscle Cell-Mediated Neointima Formation by Suppressing Akt-Dependent Signaling.

Authors:  Hong Zhi; Fu-Han Gong; Wen-Lin Cheng; Kongbo Zhu; Long Chen; Yuyu Yao; Xingzhou Ye; Xue-Yong Zhu; Hongliang Li
Journal:  J Am Heart Assoc       Date:  2018-06-10       Impact factor: 5.501

Review 4.  Chlamydia pneumoniae-Mediated Inflammation in Atherosclerosis: A Meta-Analysis.

Authors:  Simone Filardo; Marisa Di Pietro; Alessio Farcomeni; Giovanna Schiavoni; Rosa Sessa
Journal:  Mediators Inflamm       Date:  2015-08-09       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.